In today’s briefing:
- EuBiologics (206650 KS): Base Business Recovery; COVID Vaccine Undergoing Phase 3 Trial
EuBiologics (206650 KS): Base Business Recovery; COVID Vaccine Undergoing Phase 3 Trial
- Eubiologics (206650 KS) signed contract with UNICEF to deliver 67.1 million doses of its oral cholera vaccine, Euvichol-Plus, through 2023. Euvichol-Plus is the cash cow for the company.
- The company’s COVID-19 vaccine EuCorVac-19 is in phase 3 trial and is one of the early movers among Korean vaccine manufacturers in terms of clinical timeline.
- EuBiologics has successfully diversified portfolio and its pipeline of non-cholera vaccine and non-vaccine product candidates are also progressing, thereby lending long-term visibility beyond COVID.
Before it’s here, it’s on Smartkarma
